What is the share price of Genomic Valley Biotech Ltd (GVBL) today?
The share price of GVBL as on 10th July 2025 is ₹50.50. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Genomic Valley Biotech Ltd (GVBL) share?
The past returns of Genomic Valley Biotech Ltd (GVBL) share are- Past 1 week: 4.43%
- Past 1 month: 6.61%
- Past 3 months: -12.93%
- Past 6 months: -41.14%
- Past 1 year: 17.44%
- Past 3 years: 47.88%
- Past 5 years: 242.61%
What are the peers or stocks similar to Genomic Valley Biotech Ltd (GVBL)?
The peers or stocks similar to Genomic Valley Biotech Ltd (GVBL) include:What is the market cap of Genomic Valley Biotech Ltd (GVBL) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Genomic Valley Biotech Ltd (GVBL) is ₹15.43 Cr as of 10th July 2025.What is the 52 week high and low of Genomic Valley Biotech Ltd (GVBL) share?
The 52-week high of Genomic Valley Biotech Ltd (GVBL) is ₹108.15 and the 52-week low is ₹39.52.What is the PE and PB ratio of Genomic Valley Biotech Ltd (GVBL) stock?
The P/E (price-to-earnings) ratio of Genomic Valley Biotech Ltd (GVBL) is 42.85. The P/B (price-to-book) ratio is 4.36.Which sector does Genomic Valley Biotech Ltd (GVBL) belong to?
Genomic Valley Biotech Ltd (GVBL) belongs to the Health Care sector & Biotechnology sub-sector.How to buy Genomic Valley Biotech Ltd (GVBL) shares?
You can directly buy Genomic Valley Biotech Ltd (GVBL) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Genomic Valley Biotech Ltd
GVBL Share Price
50.501.21% (-0.62)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
GVBL Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
GVBL Performance & Key Metrics
GVBL Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 44.07 | 4.36 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.59 | 6.40 | 0.79% |
GVBL Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
GVBL Company Profile
Genomic Valley Biotech Ltd is conducting research in the field of Biotechnology (Plant & Animal) and also to undertake commercial production of Plant Tissue Cultured Plants of different species to feed the genetically improved plant market
BIOCON
PE Ratio
49.05
49.05
1Y Return
4.10%
4.10%
Buy Reco %
73.33
73.33
ONESOURCE
PE Ratio
-1,270.92
-1,270.92
1Y Return
16.61%
16.61%
Buy Reco %
100.00
100.00
SAILIFE
PE Ratio
95.98
95.98
1Y Return
2.41%
2.41%
Buy Reco %
66.67
66.67
ACUTAAS
PE Ratio
58.51
58.51
1Y Return
66.03%
66.03%
Buy Reco %
100.00
100.00
PANACEABIO
PE Ratio
-298.57
-298.57
1Y Return
193.21%
193.21%
Buy Reco %
0.00
0.00
GVBL Forecast
GVBL Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
GVBL
GVBL
Income
Balance Sheet
Cash Flow
Annual Normal View
GVBL Income Statement
GVBL Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.52 | 0.62 | 1.00 | 0.86 | 0.21 | 0.57 | 2.76 | 0.17 | 0.85 | 0.85 | ||||||||||
Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.58 | 0.00 | 0.40 | 0.41 | ||||||||||
| Power & Fuel Cost | 0.01 | 0.01 | 0.05 | 0.02 | 0.00 | 0.01 | 0.00 | 0.00 | ||||||||||||
| Employee Cost | 0.25 | 0.34 | 0.27 | 0.18 | 0.09 | 0.14 | 0.15 | 0.04 | ||||||||||||
| Selling & Administrative Expenses | 0.10 | 0.09 | 0.14 | 0.09 | 0.08 | 0.13 | 0.09 | 0.11 | ||||||||||||
| Operating & Other expenses | 0.18 | 0.05 | 0.11 | -0.00 | 0.18 | 0.17 | 0.28 | -0.00 | ||||||||||||
EBITDA | -0.02 | 0.13 | 0.43 | 0.57 | -0.14 | 0.12 | 0.66 | 0.02 | 0.45 | 0.44 | ||||||||||
| Depreciation/Amortization | 0.04 | 0.08 | 0.19 | 0.18 | 0.19 | 0.08 | 0.01 | 0.00 | 0.00 | — | ||||||||||
| PBIT | -0.06 | 0.05 | 0.24 | 0.39 | -0.33 | 0.04 | 0.65 | 0.02 | 0.45 | 0.44 | ||||||||||
| Interest & Other Items | 0.00 | 0.00 | 0.00 | 0.18 | 0.18 | 0.04 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| PBT | -0.06 | 0.05 | 0.24 | 0.21 | -0.51 | 0.00 | 0.65 | 0.02 | 0.45 | 0.44 | ||||||||||
| Taxes & Other Items | 0.00 | 0.02 | 0.00 | -0.08 | 0.06 | 0.01 | 0.00 | 0.00 | 0.09 | 0.09 | ||||||||||
| Net Income | -0.06 | 0.03 | 0.24 | 0.29 | -0.57 | -0.01 | 0.65 | 0.02 | 0.36 | 0.35 | ||||||||||
| EPS | -0.20 | 0.10 | 0.79 | 0.95 | -1.87 | -0.03 | 2.13 | 0.07 | 1.17 | 1.15 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
GVBL Company Updates
GVBL Stock Peers
GVBL Past Performance & Peer Comparison
GVBL Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareBiotechnology
Compare valuation-basic on Screener
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Genomic Valley Biotech Ltd | 42.85 | 4.36 | — |
| Biocon Ltd | 49.05 | 1.97 | 0.30% |
| Onesource Specialty Pharma Ltd | -1,270.92 | 57.68 | — |
| Sai Life Sciences Ltd | 95.98 | 16.75 | — |
GVBL Stock Price Comparison
Compare GVBL with any stock or ETFCompare GVBL with any stock or ETF
GVBL
GVBL Holdings
GVBL Shareholdings
GVBL Promoter Holdings Trend
GVBL Promoter Holdings Trend
Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 7.89%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
GVBL Institutional Holdings Trend
GVBL Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
GVBL Shareholding Pattern
GVBL Shareholding Pattern
GVBL Shareholding History
GVBL Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing GVBL stock
smallcases containing GVBL stock
Looks like this stock is not in any smallcase yet.
GVBL Events
GVBL Events
GVBL Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
GVBL has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
GVBL Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
GVBL has not given any dividends in last 5 years
GVBL Dividends
GVBL Dividends
Hmm, looks like data is unavailable here. Please come back after some timeGVBL Stock News & Opinions
GVBL Stock News & Opinions
Articles & Videos
Earnings
Genomic Valley Biotech reports standalone net loss of Rs 0.08 crore in the March 2025 quarter
Net Loss of Genomic Valley Biotech reported to Rs 0.08 crore in the quarter ended March 2025 as against net loss of Rs 0.04 crore during the previous quarter ended March 2024. Sales reported to Rs 0.26 crore in the quarter ended March 2025. There were no Sales reported during the previous quarter ended March 2024. For the full year,net profit rose 1700.00% to Rs 0.36 crore in the year ended March 2025 as against Rs 0.02 crore during the previous year ended March 2024. Sales rose 394.12% to Rs 0.84 crore in the year ended March 2025 as against Rs 0.17 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales0.260 0 0.840.17 394 OPM %3.850 -53.5711.76 - PBDT0.01-0.04 LP 0.450.02 2150 PBT0.01-0.04 LP 0.450.02 2150 NP-0.08-0.04 -100 0.360.02 1700 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Genomic Valley Biotech announces board meeting date
Genomic Valley Biotech will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Genomic Valley Biotech standalone net profit rises 700.00% in the December 2024 quarter
Net profit of Genomic Valley Biotech rose 700.00% to Rs 0.16 crore in the quarter ended December 2024 as against Rs 0.02 crore during the previous quarter ended December 2023. Sales rose 450.00% to Rs 0.22 crore in the quarter ended December 2024 as against Rs 0.04 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales0.220.04 450 OPM %72.7350.00 - PBDT0.160.02 700 PBT0.160.02 700 NP0.160.02 700 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Genomic Valley Biotech to convene board meeting
Genomic Valley Biotech will hold a meeting of the Board of Directors of the Company on 14 February 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Genomic Valley Biotech schedules AGM
Genomic Valley Biotech announced that the Annual General Meeting(AGM) of the company will be held on 30 December 2024.Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Genomic Valley Biotech to convene board meeting
Genomic Valley Biotech will hold a meeting of the Board of Directors of the Company on 6 December 2024Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Genomic Valley Biotech standalone net profit rises 650.00% in the September 2024 quarter
Net profit of Genomic Valley Biotech rose 650.00% to Rs 0.15 crore in the quarter ended September 2024 as against Rs 0.02 crore during the previous quarter ended September 2023. Sales rose 200.00% to Rs 0.21 crore in the quarter ended September 2024 as against Rs 0.07 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales0.210.07 200 OPM %66.6728.57 - PBDT0.150.02 650 PBT0.150.02 650 NP0.150.02 650 Powered by Capital Market - Live
9 months agoCapital Market - Live
Corporate
Genomic Valley Biotech to discuss results
Genomic Valley Biotech will hold a meeting of the Board of Directors of the Company on 7 October 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Genomic Valley Biotech standalone net profit rises 333.33% in the June 2024 quarter
11 months agoBusiness Standard
Earnings
Genomic Valley Biotech standalone net profit rises 333.33% in the June 2024 quarter
Net profit of Genomic Valley Biotech rose 333.33% to Rs 0.13 crore in the quarter ended June 2024 as against Rs 0.03 crore during the previous quarter ended June 2023. Sales rose 166.67% to Rs 0.16 crore in the quarter ended June 2024 as against Rs 0.06 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales0.160.06 167 OPM %81.2550.00 - PBDT0.130.03 333 PBT0.130.03 333 NP0.130.03 333 Powered by Capital Market - Live
11 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -0.23%, vs industry avg of 21.18%
Over the last 5 years, market share decreased from 0.01% to 0%
Over the last 5 years, net income has grown at a yearly rate of 4.42%, vs industry avg of 20.36%